Unlocking the Potential of STE – Insights from Our Analysts

By Susan Ramirez • Tuesday, May 12 10:50 • Permanent Link

Large-cap Health Care company STERIS has moved 3.0% so far today on a volume of 559,665, compared to its average of 788,363. In contrast, the S&P 500 index moved -1.0%.

Anyone interested in buying STE should be aware of the facts below:

STERIS's current price is 106.7% above its Graham number of $100.61, which implies that at its current valuation it does not offer a margin of safety
STERIS has moved -12.7% over the last year, and the S&P 500 logged a change of 25.9%
Based on its trailing earnings per share of 7.17, STERIS has a trailing 12 month Price to Earnings (P/E) ratio of 29.0 while the S&P 500 average is 29.3
STE has a forward P/E ratio of 17.1 based on its forward 12 month price to earnings (EPS) of $12.14 per share
The company has a price to earnings growth (PEG) ratio of 1.58 — a number near or below 1 signifying that STERIS is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.85 compared to its sector average of 3.19
STERIS plc provides infection prevention products and services worldwide.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.